Analyst Consensus ?
ConsensusHold33 ratings
Bullish1236.4%
Neutral1854.5%
Bearish39.1%
Quest Diagnostics Incorporated · DGX · FY2024 Q4 · Calendar Q1 2025
Quest Diagnostics: acquisitions and advanced testing support 2025 outlook
The supplied analysis supports a constructive but qualified view: acquisition activity, Advanced Diagnostics, consumer testing, and automation provide several avenues for continued growth, while integration, compliance investment, pricing, and utilization are the key tests of whether that growth translates into durable margin expansion.
Reported Before market openNYSEHealthcare
$26.34B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $2.19
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.58B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+5.6%
Event window
SPY move
+0.5%
Same window
Abnormal move
+5.1%
Stock minus SPY
Volume
2.9×
Versus trailing sessions
Subsequent drift
+5.3%
Up to 20 sessions
DGXSPY benchmark
Ask FN2 about DGX FY2024 Q4
Transcript, numbers and history already loaded
What drove DGX's +5.6% move after FY2024 Q4 earnings?What changed in DGX's guidance and outlook in FY2024 Q4?Give me the bull and bear case for DGX after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis shifts the focus toward 2025 execution: integrating LifeLabs and other acquisitions, scaling Advanced Diagnostics and consumer testing, increasing AI and automation deployment, and funding IT modernization and LDT compliance.
Guidance delta
Management provided 2025 revenue, adjusted EPS, and capex guidance; the supplied analysis does not quantify a prior-quarter guidance change.
Key takeaways
- Growth was described as a mix of organic gains, acquisitions, and Advanced Diagnostics expansion.
- Consumer-initiated testing on Questhealth.com and brain-health testing were highlighted as growth areas.
- Management expects margin expansion despite initial LifeLabs integration dilution.
- Automation, AI, and IT modernization remain central to productivity and operating plans.
Management priorities
- Integrate LifeLabs and other hospital outreach acquisitions.
- Expand Haystack MRD, brain-health, and other Advanced Diagnostics offerings.
- Continue AI-driven laboratory automation and broader IT modernization.
- Develop the consumer testing platform and health-plan relationships.
Follow DGX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$236.11Current
$125Low
$199.81Average
$260High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | Overweight | Maintain | Oct 7, 2026 |
| Truist Securities | Hold | Hold | Maintain | Sep 21, 2026 |
| UBS | Neutral | Neutral | Maintain | Sep 8, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 28, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 24, 2026 |
| Baird | Neutral | Neutral | Maintain | Jul 24, 2026 |
| Evercore ISI Group | In Line | In Line | Maintain | Apr 8, 2026 |
| Jefferies | Buy | Buy | Maintain | Feb 11, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Feb 10, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Oct 27, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Oct 21, 2025 |
| Deutsche Bank | Hold | Hold | Maintain | Jul 23, 2025 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Dec 17, 2024 |
| B of A Securities | Buy | Buy | Maintain | Dec 13, 2024 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Feb 3, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Jan 25, 2023 |
| Keybanc | Overweight | Overweight | Maintain | Dec 13, 2021 |
| Argus Research | Buy | Hold | Upgrade | Oct 21, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 21, 2020 |
| CFRA | Hold | Strong Buy | Downgrade | Apr 22, 2020 |
| Bank of America | Neutral | Underperform | Upgrade | Dec 19, 2019 |
| Canaccord Genuity | Buy | Buy | Maintain | Jul 24, 2019 |
| Goldman Sachs | Sell | Neutral | Downgrade | Jul 15, 2019 |
| Argus | Hold | Buy | Downgrade | Jan 31, 2019 |
| William Blair | Outperform | Market Perform | Upgrade | Jun 8, 2018 |
| Raymond James | Market Perform | Outperform | Downgrade | Sep 25, 2017 |
| Jyske Bank | Sell | Sell | Maintain | Jun 24, 2016 |
| JMP Securities | Perform | Market Perform | Maintain | Mar 27, 2015 |
| ISI Group | Neutral | Neutral | Maintain | Nov 19, 2013 |
| Craig-Hallum | Buy | Buy | Maintain | Sep 19, 2013 |
| Maxim Group | Buy | Hold | Upgrade | Aug 8, 2013 |
| Oppenheimer | Underperform | Underperform | Maintain | Jan 28, 2013 |
| Macquarie | Neutral | Underperform | Upgrade | Nov 20, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $236.11. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $250 | $234.03 | +5.9% | Oct 19, 2026 |
| Barclays | Luke Sergott | $260 | $228.46 | +10.1% | Oct 7, 2026 |
| Truist Financial | Analyst unavailable | $260 | $246.48 | +10.1% | Sep 21, 2026 |
| UBS | Analyst unavailable | $245 | $235.58 | +3.8% | Sep 8, 2026 |
| Argus Research | Analyst unavailable | $260 | $235.34 | +10.1% | Jul 29, 2026 |
| UBS | Kevin Caliendo | $232 | $231.3 | -1.7% | Jul 24, 2026 |
| Robert W. Baird | Analyst unavailable | $255 | $227.9 | +8.0% | Jul 24, 2026 |
| Barclays | Analyst unavailable | $250 | $227.9 | +5.9% | Jul 23, 2026 |
| Jefferies | Analyst unavailable | $245 | $227.9 | +3.8% | Jul 23, 2026 |
| Robert W. Baird | Analyst unavailable | $236 | $207.44 | -0.0% | Jul 13, 2026 |
| Evercore ISI | Analyst unavailable | $225 | $205.18 | -4.7% | Apr 21, 2026 |
| Jefferies | Analyst unavailable | $225 | $205.18 | -4.7% | Apr 21, 2026 |
| Evercore ISI | Analyst unavailable | $210 | $198.81 | -11.1% | Apr 8, 2026 |
| Mizuho Securities | Analyst unavailable | $235 | $209.32 | -0.5% | Feb 12, 2026 |
| UBS | Analyst unavailable | $210 | $206.72 | -11.1% | Feb 11, 2026 |
| Truist Financial | Analyst unavailable | $220 | $205.62 | -6.8% | Feb 11, 2026 |
| Evercore ISI | Elizabeth Anderson | $220 | $205.43 | -6.8% | Feb 11, 2026 |
| Robert W. Baird | Analyst unavailable | $219 | $205.35 | -7.2% | Feb 11, 2026 |
| Jefferies | Tycho Peterson | $220 | $205.24 | -6.8% | Feb 10, 2026 |
| Barclays | Analyst unavailable | $210 | $182.35 | -11.1% | Jan 30, 2026 |
| Piper Sandler | Analyst unavailable | $200 | $182.18 | -15.3% | Oct 27, 2025 |
| Truist Financial | Analyst unavailable | $205 | $184.64 | -13.2% | Oct 22, 2025 |
| Morgan Stanley | Erin Wright | $207 | $183.18 | -12.3% | Oct 22, 2025 |
| Barclays | Analyst unavailable | $195 | $183.18 | -17.4% | Oct 22, 2025 |
| Jefferies | Analyst unavailable | $215 | $183.34 | -8.9% | Oct 21, 2025 |
| Leerink Partners | Analyst unavailable | $210 | $184.1 | -11.1% | Oct 21, 2025 |
| UBS | Kevin Caliendo | $190 | $186.82 | -19.5% | Oct 17, 2025 |
| Mizuho Securities | Analyst unavailable | $210 | $186.82 | -11.1% | Oct 17, 2025 |
| Truist Financial | Analyst unavailable | $195 | $184 | -17.4% | Oct 14, 2025 |
| Evercore ISI | Analyst unavailable | $190 | $181.89 | -19.5% | Oct 8, 2025 |
| Barclays | Analyst unavailable | $190 | $182.07 | -19.5% | Oct 2, 2025 |
| Robert W. Baird | Analyst unavailable | $194 | $178.66 | -17.8% | Aug 25, 2025 |
| Evercore ISI | Elizabeth Anderson | $185 | $170.48 | -21.6% | Jul 23, 2025 |
| Redburn Partners | Jamie Clark | $195 | $167.96 | -17.4% | Apr 2, 2025 |
| Piper Sandler | David Westenberg | $180 | $162.47 | -23.8% | Feb 3, 2025 |
| Truist Financial | David MacDonald | $182 | $163.1 | -22.9% | Jan 31, 2025 |
| Robert W. Baird | Eric Coldwell | $189 | $163.1 | -20.0% | Jan 31, 2025 |
| Citigroup | Patrick Donnelly | $185 | $157.47 | -21.6% | Oct 23, 2024 |
| Leerink Partners | Michael Cherny | $165 | $157.47 | -30.1% | Oct 23, 2024 |
| Barclays | Stephanie Davis | $168 | $157.47 | -28.8% | Oct 23, 2024 |
| Robert W. Baird | Eric Coldwell | $182 | $157.47 | -22.9% | Oct 23, 2024 |
| CFRA | Paige Meyer | $178 | $157.46 | -24.6% | Oct 22, 2024 |
| Truist Financial | David MacDonald | $165 | $150.79 | -30.1% | Oct 7, 2024 |
| Mizuho Securities | Ann Hynes | $160 | $143.21 | -32.2% | Jul 29, 2024 |
| Robert W. Baird | Eric Coldwell | $154 | $140.96 | -34.8% | Jul 24, 2024 |
| Truist Financial | David MacDonald | $158 | $144.11 | -33.1% | Jul 15, 2024 |
| Barclays | Stephanie Davis | $144 | $137.55 | -39.0% | Apr 25, 2024 |
| Jefferies | Brian Tanquilut | $155 | $127.42 | -34.4% | Feb 7, 2024 |
| Wells Fargo | Analyst unavailable | $140 | $143.29 | -40.7% | Feb 3, 2023 |
| Morgan Stanley | Analyst unavailable | $158 | $155.5 | -33.1% | Jan 6, 2023 |
| Citigroup | Analyst unavailable | $125 | $149.27 | -47.1% | Nov 17, 2022 |
| Morgan Stanley | Analyst unavailable | $142 | $136.13 | -39.9% | May 3, 2022 |
| Wells Fargo | Analyst unavailable | $150 | $133.75 | -36.5% | Apr 25, 2022 |
| Citigroup | Ralph Giacobbe | $175 | $140 | -25.9% | Apr 9, 2022 |
| Deutsche Bank | Pito Chickering | $190 | $142.3 | -19.5% | Jan 15, 2022 |
| KeyBanc | Donald Hooker | $170 | $161.75 | -28.0% | Dec 13, 2021 |
| Credit Suisse | A.J. Rice | $150 | $155.22 | -36.5% | Sep 9, 2021 |
Track every rating change on DGX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationQuest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients.…
Historical context
All DGX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ABT Abbott Laboratories | FY2026 Q3 · Calendar Q4 2026 | 0.0% | -1.9% | Abbott plans nutrition spin-off as Q3 growth holds, guidance falls |
| DHR Danaher Corporation | FY2026 Q3 · Calendar Q4 2026 | +9.9% | +4.3% | Danaher Raises EPS Guidance as Q3 Core Growth Reaches 5.5% |
| TMO Thermo Fisher Scientific Inc. | FY2026 Q3 · Calendar Q4 2026 | +4.4% | +1.0% | Thermo Fisher raises 2026 guidance as pharma services and AI support growth |
| ELV Elevance Health Inc. | FY2026 Q3 · Calendar Q4 2026 | +48.4% | -1.4% | Elevance raises EPS outlook as Medicaid and Carelon improve |
| ISRG Intuitive Surgical, Inc. | FY2026 Q3 · Calendar Q4 2026 | +13.2% | -3.6% | Intuitive Surgical: Strong Q3 growth, with pricing and policy risks ahead |
Latest beats and misses
Who reports nextBeat on EPS
- WCNFY2026 Q3 · October 21, 2026+3.9% EPS+8.8% move
- KMIFY2026 Q3 · October 21, 2026+9.2% EPS+1.2% move
- TXNFY2026 Q3 · October 21, 2026+7.4% EPS+2.5% move
- SEICFY2026 Q3 · October 21, 2026+3.8% EPS+1.2% move
- CSXFY2026 Q3 · October 21, 2026+7.3% EPS+0.7% move
- IBMFY2026 Q3 · October 21, 2026+3.5% EPS+3.9% move
Missed on EPS
- METAFY2026 Q3 · October 21, 2026-41.4% EPS+0.5% move
- LVSFY2026 Q3 · October 21, 2026-20.9% EPS-1.7% move
- MCOFY2026 Q3 · October 21, 2026-2.6% EPS+1.2% move
- CCIFY2026 Q3 · October 21, 2026-2.5% EPS-3.1% move
- PACFY2026 Q3 · October 20, 2026-2.2% EPS+7.1% move
- AGNCZFY2026 Q3 · October 19, 2026-0.6% EPS+0.3% move
Get the DGX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-16T00:01:26.053560+00:00
- Polygon adjusted daily market bars · 2026-10-22T11:50:43.711644+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-22T11:50:43.708866+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-22. For educational purposes only; not investment advice.